

Exhibit B

<!--StartFragment-->RESULT 2

AAB42635

ID AAB42635 standard; protein; 401 AA.

XX

AC AAB42635;

XX

DT 08-FEB-2001 (first entry)

XX

DE Human ORFX ORF2399 polypeptide sequence SEQ ID NO:4798.

XX

KW Human; open reading frame; ORFX; detection; cytostatic; hepatotropic;
 KW vulnerary; antipsoriatic; antiparkinsonian; nootropic; neuroprotective;
 KW anticonvulsant; osteopathic; antiarthritic; immunosuppressant; cardiant;
 KW immunostimulant; thrombolytic; coagulant; vasotropic; antidiabetic;
 KW hypotensive; dermatological; immunosuppressive; antiinflammatory;
 KW antiviral; antibacterial; antifungal; antirheumatic; antithyroid;
 KW antianaemic; gene therapy; cancer; proliferative disorder; hypertension;
 KW neurodegenerative disorder; osteoarthritis; graft vs host disease;
 KW cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;
 KW cholesterol ester storage; systemic lupus erythematosus; infection;
 KW severe combined immunodeficiency; malaria; autoimmune disorder; asthma;
 KW allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;
 KW bone damage; cartilage damage; antiinflammatory disease; coagulation;
 KW thrombosis; contraceptive.

XX

OS Homo sapiens.

XX

PN WO200058473-A2.

XX

PD 05-OCT-2000.

XX

PF 31-MAR-2000; 2000WO-US008621.

XX

PR 31-MAR-1999; 99US-0127607P.

PR 02-APR-1999; 99US-0127636P.

PR 05-APR-1999; 99US-0127728P.

PR 30-MAR-2000; 2000US-00540763.

XX

PA (CURA-) CURAGEN CORP.

XX

PI Shimkets RA, Leach M;

XX

DR WPI; 2000-602362/57.

XX

DR N-PSDB; AAC76844.

XX

PT Novel nucleic acids and peptides derived from open reading frame X,
 PT useful for treating e.g. cancers, proliferative disorders,
 PT neurodegenerative disorders and cardiovascular disease.

XX

PS Claim 11; Page 3982-3983; 5507pp; English.

XX

CC AAC74446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,
 CC which represent the human ORFX open reading frames 1 to 3161. The ORFX
 CC sequences have activities such as: cytostatic; hepatotropic; vulnerary;
 CC antipsoriatic; antiparkinsonian; nootropic; neuroprotective; osteopathic;
 CC anticonvulsant; antiarthritic; immunosuppressant; immunostimulant;
 CC cardiant; thrombolytic; coagulant; vasotropic; antidiabetic; hypotensive;
 CC dermatological; immunosuppressive; antiinflammatory; antibacterial;
 CC antiviral; antifungal; antirheumatic; antithyroid; and antianaemic. The
 CC sequences can be used for determining the presence of or predisposition
 CC to, or preventing or treating pathological conditions associated with an
 CC ORFX-associated disorder. The nucleic acids can be used to express ORFX
 CC proteins in gene therapy vectors. The proteins and nucleic acids may be
 CC used to treat cancers, proliferative disorders, neurodegenerative
 CC disorders, osteoarthritis, graft vs host disease, cardiovascular disease,
 CC diabetes mellitus, hypertension, hypothyroidism, cholesterol ester
 CC storage, systemic lupus erythematosus, severe combined immunodeficiency
 CC (SCID), AIDS, viral, bacterial or fungal infection, malaria, autoimmune
 CC disorders, asthma, allergies, aplastic anaemia, burns, wounds, bone and
 CC cartilage damage, nocturnal haemoglobinuria, antiinflammatory disease; to
 CC enhance coagulation; to inhibit thrombosis; and as a contraceptive

XX

SQ Sequence 401 AA;

Query Match 100.0%; Score 1784; DB 3; Length 401;
 Best Local Similarity 100.0%; Pred. No. 2.5e-141;

Matches 349; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTIGEMLRSLTKLEWFSTLFPRIQKIDQKTRPRKIKKDGKEGAEIDRHVER 60
|||||

Db 53 MTIGEMLRSLTKLEWFSTLFPRIQKIDQKTRPRKIKKDGKEGAEIDRHVER 112

Qy 61 RRSRSPRRSLSPRRSPRRSRSHHREGHGSSSFDRELEREKERQRLEREAKEREKERR 120
|||||

Db 113 RRSRSPRRSLSPRRSPRRSRSHHREGHGSSSFDRELEREKERQRLEREAKEREKERR 172

Qy 121 SRSIDRGLERRSRSRERHRSRSDRKGDRDRDREREKENERGRRDRDYDKERGNE 180
|||||

Db 173 SRSIDRGLERRSRSRERHRSRSDRKGDRDRDREREKENERGRRDRDYDKERGNE 232

Qy 181 REKERERSRERSKEQSRSGEVEEKKHKEDKDDRRHRDDKRDSSKEKKHSRSDRERKHRS 240
|||||

Db 233 REKERERSRERSKEQSRSGEVEEKKHKEDKDDRRHRDDKRDSSKEKKHSRSDRERKHRS 292

Qy 241 RSRSRNAGKRSRSDRSGEVEEKKHKEDKDDRRHRDDKRDSSKEKKHSRSDRERKHRS 300
|||||

Db 293 RSRSRNAGKRSRSDRSGEVEEKKHKEDKDDRRHRDDKRDSSKEKKHSRSDRERKHRS 352

Qy 301 RKRSRSKERSHSHRSDSKDQSDKHDRRRSQSIEQESQEKQHKNKDETV 349
|||||

Db 353 RKRSRSKERSHSHRSDSKDQSDKHDRRRSQSIEQESQEKQHKNKDETV 401

<!--EndFragment-->